News | August 15, 2024
Glenmark Pharma reports Q1 FY25 consolidated PAT at Rs. 340.2 Cr
India Business grew by 11.9% YoY to Rs. 1196.2 crore
India Business grew by 11.9% YoY to Rs. 1196.2 crore
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
Our centers are performing as expected or even better
The company has seamlessly integrated the business acquired from Yash Pharma into Jagsonpal and are now confident of aligning the margins of the acquired business with that of Jagsonpal ahead of schedule
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
Achievement of This Major Milestone Further Simplifies and Strengthens the Company and Positions Viatris to Achieve its Key Priorities and Accelerate Future Growth
The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23
Subscribe To Our Newsletter & Stay Updated
